Recent 8-K filings for CLRB

• May 18, 2026 20:15 UTC leadership materiality 0.55 neutral item 5.02

  Cellectar director Loren not standing for reelection; Nantahala analyst Gu appointed to board

  Dr. Stefan Loren will not stand for reelection at 2026 annual meeting; no disagreement with the company.

• May 14, 2026 11:20 UTC earnings materiality 0.85 positive item 2.02item 9.01

  Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing

  Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.

• May 08, 2026 23:59 UTC other_material materiality 0.80 positive item 1.01item 3.02item 8.01item 9.01

  Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

  Gross proceeds ~$35M; issued 1.6M registered shares, 2.1M unregistered, and warrants for 9.5M+13.2M shares.

• Mar 04, 2026 23:59 UTC earnings materiality 0.60 neutral item 2.02item 9.01

  Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026

  Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.

• Nov 13, 2025 23:59 UTC earnings materiality 0.60 neutral item 2.02item 9.01

  Cellectar Q3 net loss $4.4M ($1.41/sh); cash $12.6M; progress on EU conditional marketing for iopofosine

  Net loss narrowed to $4.4M ($1.41/sh) from $14.7M ($11.18/sh) YoY; R&D spending fell to $2.5M.

• Oct 10, 2025 23:59 UTC other_material materiality 0.75 positive item 1.01item 2.02item 3.02item 3.03item 8.01item 9.01

  Cellectar raises ~$5.8M via warrant exercise; prelim cash $12.6M as of Sep 30

  Gross proceeds of ~$5.8M from exercise of 1,048,094 existing warrants at $5.25/share; holders paid $0.125 per new warrant.

• Oct 06, 2025 23:59 UTC regulatory materiality 0.75 positive item 7.01item 8.01item 9.01

  EMA confirms iopofosine I 131 eligible for Conditional Marketing Authorization in post-BTKi WM

  SAWP advised filing a CMA for iopofosine I 131 in post-BTKi refractory WM could be acceptable.

• Aug 14, 2025 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  Cellectar to pursue accelerated NDA for iopofosine I 131 in WM; Q2 net loss $5.4M

  Plans NDA submission for accelerated approval of iopofosine I 131 in WM, subject to sufficient funding and confirmatory trial initiation.

• Jun 26, 2025 23:59 UTC other_material materiality 0.65 neutral item 8.01

  Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing

  CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.

• Jun 25, 2025 23:59 UTC other materiality 0.50 neutral item 3.03item 5.03item 9.01

  Cellectar Biosciences completes 1-for-30 reverse stock split effective June 24, 2025

  Reverse split ratio set at 1-for-30 for common stock, par value $0.00001.

• Jun 18, 2025 23:59 UTC other_material materiality 0.50 neutral item 8.01item 9.01

  Cellectar Biosciences announces 1-for-30 reverse stock split; effective June 24, 2025

  Approved by stockholders at June 13, 2025 annual meeting; board set final ratio as 1-for-30.

• Jun 13, 2025 23:59 UTC other_material materiality 0.50 neutral item 5.07

  Cellectar shareholders approve reverse stock split, re-elect directors

  Elected James V. Caruso and Frederick W. Driscoll as Class II directors; Caruso 5,478,892 for, Driscoll 6,207,218 for.

• Jun 05, 2025 23:59 UTC other_material materiality 0.40 neutral item 1.01item 3.02item 3.03item 7.01item 9.01

  Cellectar Biosciences raises $2.5M via warrant exercise inducement at $0.3041/share

  Gross proceeds ~$2.5M from immediate exercise of 8,301,322 outstanding warrants at $0.3041/share.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

4 positive 0 negative 9 neutral

source · CLRB on sec.gov